Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

LNCaP cancer cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5 alpha Reductase (3) Adenosine Receptor (1) Akt (3) AMPK (1) Androgen Receptor (40) Apoptosis (22) Atg4 (1) Aurora Kinase (1) Autophagy (3) AUTOTACs (1) Bacterial (1) Bcl-2 Family (5) Biochemical Assay Reagents (3) BMX Kinase (1) c-Myc (1) Caspase (8) Cathepsin (1) CDK (3) Cytochrome P450 (3) Deubiquitinase (1) DNA/RNA Synthesis (1) Drug Derivative (3) Drug Metabolite (3) E1/E2/E3 Enzyme (1) EGFR (1) Endogenous Metabolite (2) Epigenetic Reader Domain (4) Ferroptosis (1) Fluorescent Dye (2) HDAC (4) Histone Acetyltransferase (4) Histone Demethylase (7) Histone Methyltransferase (2) HSP (1) Insecticide (1) Isotope-Labeled Compounds (4) Kallikrein (1) Kinesin (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (1) LYTACs (2) MDM-2/p53 (1) MetAP (1) Mitochondrial Metabolism (1) Molecular Glues (1) Monoamine Oxidase (3) mTOR (1) NEKs (1) NF-κB (1) Opioid Receptor (2) Parasite (1) PARP (5) PD-1/PD-L1 (1) PGE synthase (1) Phospholipase (1) Pim (1) PROTAC Linkers (1) PROTACs (12) PSMA (11) Pyroptosis (1) RAD51 (1) Radionuclide-Drug Conjugates (RDCs) (2) Reactive Oxygen Species (ROS) (3) Reference Standards (3) Ser/Thr Protease (1) Src (1) Survivin (1) TNF Receptor (1) Topoisomerase (1) Transmembrane Glycoprotein (1) Zinc Finger Protein (1)
By Research Areas:	Cancer (114) Endocrinology (2) Infection (4) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (2)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (1)

118

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) BCRP TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-158113

CBPD-409	Histone Acetyltransferase PROTACs	Cancer
CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC₅₀ of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC₅₀s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .

HY-13915

NSC348884 3 Publications Verification	Apoptosis	Cancer
NSC348884 is a nucleophosmin (NPM) inhibitor, it disrupts oligomer formation and induces apoptosis, inhibits cell proliferation with IC₅₀s of 1.7-4.0 μM in distinct cancer cell lines. NSC348884 can be used for the research of cancer .

HY-16079

AZD3514 3 Publications Verification	Androgen Receptor	Cancer
AZD3514 is an orally activie and selective androgen receptor (AR) inhibitor. AZD3514 androgen-dependently and -independently inhibits AR signal. AZD351 down-regulates nuclear AR levels in human LNCaP prostate cancer cells in the absence of androgen with an pIC₅₀ value of 5.75. AZD3514 can be used for the research of prostate cancer .

HY-70002S1

Enzalutamide-d6 MDV3100-d₆	Isotope-Labeled Compounds Androgen Receptor	Cancer
Enzalutamide-d₆ (MDV3100-d₆) is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC₅₀ of 36 nM in LNCaP prostate cells .

HY-162706

BSJ-5-63 1 Publications Verification	PROTACs CDK	Cancer
BSJ-5-63 is a potent CDK12, CDK7, CDK9 PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer (Pink: ligand for target protein (HY-150948); black: linker (HY-W140827); Blue: E3 ligase ligand (HY-112078)) .

HY-170329

PROTAC AR Degrader-8	PROTACs Androgen Receptor Apoptosis	Cancer
PROTAC AR Degrader-8 is the PROTAC degrader for androgen receptor (AR) that degrades AR-FL with DC₅₀s of 0.018 μM and 0.14 μM in 22Rv1 cell and LNCaP cell, degrades AR-V7 with DC₅₀ of 0.026 μM in 22Rv1 cell. PROTAC AR Degrader-8 inhibits the proliferation of cancer cell 22Rv1 and LNCaP with IC₅₀ values of 0.038 μM and 1.11 μM. PROTAC AR Degrader-8 arrests cell cycle at G2/M phase, induces apoptosis in 22Rv1 cell. PROTAC AR Degrader-8 exhibits anticancer efficacy in mouse and zebrafish model. PROTAC AR Degrader-8 can be used for the research of prostate cancer, castration-resistant prostate cancer .

HY-149433

BWA-522	PROTACs Androgen Receptor Apoptosis	Cancer
BWA-522 is an orally active PROTAC degrader targeting full-length androgen receptor (AR-FL) and androgen receptor splice variant 7 (AR-V7). BWA-522 antagonizes the N-terminal domain (AR-NTD) of the androgen receptor, suppresses AR downstream signaling proteins and induces cancer cells apoptosis. BWA-522 inhibits tumor growth in LNCaP xenograft mouse model. BWA-522 can be used for the research of prostate cancer .

HY-115282A

JNJ-63576253 1 Publications Verification TRC-253	Androgen Receptor	Cancer
JNJ-63576253 (TRC-253) is a potent and orally active full antagonist of androgen receptor (AR), with IC₅₀s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the research of castration-resistant prostate cancer (CRPC) .

HY-70002S

Deutenzalutamide Enzalutamide-d₃; MDV3100-d₃	Androgen Receptor Autophagy	Cancer
Deutenzalutamide (Enzalutamide-d₃) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells .

HY-133045

VHL Ligand 8	Ligands for E3 Ligase	Cancer
VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM .

HY-161369

CBPD-268	PROTACs Histone Acetyltransferase	Cancer
CBPD-268 is a potent and orally active CBP/p300 PROTAC degrader with an DC₅₀ value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Structure Note: Red, Androgen receptor degrader (HY-W248665A); Blue, CBP/p300 ligand (HY-161483); Black, Linker) .

HY-108250

(R)-Bicalutamide	Androgen Receptor	Cancer
(R)-Bicalutamide is the (R)-enantiomer of Bicalutamide (HY-14249). (R)-Bicalutamide is an androgen receptor (AR) antagonist, with antineoplastic activity. (R)-Bicalutamide is widely used for the research of prostate cancer .

HY-149862

ARD-2051 1 Publications Verification	PROTACs Androgen Receptor	Cancer
ARD-2051 is a selective and orally active androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC₅₀ values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 exhibits effective anti-tumor activity in VCaP xenograft mice model. ARD-2051 can be used for the research of prostate cancer (Pink: AR ligand (HY-400666), Blue: CRBN Ligand (HY-14658), Black: Linker) .

HY-N7510

12-O-Methylcarnosic acid 12-Methoxycarnosic acid	5 alpha Reductase	Infection Cancer
12-O-Methylcarnosic acid (12-Methoxycarnosic acid), a diterpene carnosic acid isolated from the acetone extract of Salvia microphylla, is an active constituent of 5α-reductase inhibition with an IC₅₀ value of 61.7 μM. 12-O-Methylcarnosic acid inhibits proliferation in LNCaP cells. 12-O-Methylcarnosic acid has antioxidant, anti-cancer and antimicrobial activity .

HY-133020

ARD-266	PROTACs Androgen Receptor	Cancer
ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM . ARD-266 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P1793

α-Casein (90-95)	Opioid Receptor Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology Cancer
α-Casein (90-95) is a partial agonist of opioid receptors and a copper ion ligand, with opioid activity. α-Casein (90-95) inhibits the secretion of β-hexosaminidase by rat peritoneal mast cells (PMC) with IC₅₀= 0.1 μM. α-Casein (90-95) inhibits the proliferation of prostate cancer cells LNCaP, DU145, and PC3 with IC₅₀ of 0.94 nM, 137 nM, and 6.92 nM, respectively. α-Casein (90-95) activates G_i-like proteins through a membrane-assisted, receptor-independent pathway, or reversibly binds to opioid receptors, inducing intracellular calcium release and conformational changes, and exerts the activity of promoting mast cell secretion and inhibiting tumor cell proliferation. α-Casein (90-95) can be used in the study of the mechanisms of allergic diseases and prostate cancer .

HY-151576

PRMT5:MEP50 PPI	Histone Methyltransferase	Cancer
PRMT5:MEP50 PPI is a novel PRMT5:MEP50 protein-protein interaction (PRMT5:MEP50 PPI) inhibitor, shows anti-tumor activity and anti-proliferative activity of lung and prostate cancer cells .

HY-162702

AZ'3137	PROTACs Androgen Receptor	Cancer
AZ‘3137 is an orally active PROTAC-type androgen receptor (AR) degrader with a DC₅₀ value of 22 nM. AZ‘3137 can degrade L702H mutant AR (DC₅₀ of 92 nM). AZ'3137 can inhibit cell proliferation of LNCaP, with a GI₅₀ value of 74 nM. AZ'3137 can inhibit AR signaling and tumor growth in prostate cancer mice (Pink: AR Ligand (HY-172954); Blue: CRBN ligand (HY-172955); Black: linker (HY-W262798); E3 Ligand+Linker: HY-172956) .

HY-149091

KDM5B-IN-4	Histone Demethylase	Cancer
KDM5B-IN-4 (compound 11ad) is a lysine demethylase 5B (KDM5B) inhibitor with an IC₅₀ of 0.025 μM KDM5B-IN-4 increases substrate H3K4me1/2/3 level by inhibiting KDM5B in PC-3 cells. KDM5B-IN-4 downregulates PI3K/AKT. KDM5B-IN-4 reduces tumor volume in mice and shows less toxic to organs .

HY-114256

EC1169	PSMA	Cancer
EC1169 is a cytotoxic maytansinoid conjugate that specifically binds to prostate-specific membrane antigen (PSMA). EC1169 precisely delivers the maytansinoid B hydrazide payload to PSMA-positive cells to exert antitumor activity. EC1169 only inhibits the growth of PSMA-positive cells but has no effect on PSMA-negative cells, and enables complete recovery in mice bearing PSMA-positive tumors. EC1169 exhibits safety with no body weight loss or major organ damage induced. EC1169 is used in studies of prostate cancer and other PSMA-expressing malignancies .

HY-N3999

Venuloside A ESK246	Others	Cancer
Venuloside A is a potent inhibitor of LAT3. Venuloside A inhibits the leucine uptake in LNCaP prostate cancer cells with an IC₅₀ of 8.12 μM .

HY-144636

Atg4B-IN-2	Atg4 Cathepsin Phospholipase Autophagy	Cancer
Atg4B-IN-2 is a potent competitive Atg4B inhibitor with K_i value of 3.1 μM, also possesses declining PLA₂ inhibitory potency, IC₅₀s of 11 μM and 3.5 μM for Atg4B and PLA₂, respectively. Atg4B-IN-2 enhances the anticancer activity of anti-castration-resistant prostate cancer agents via autophagy inhibition .

HY-175652

AZD9750	PROTACs Adenosine Receptor	Cancer
AZD9750 is an orally active, Cereblon (CRBN)-recruiting, androgen receptor (AR)-targeted PROTAC degrader. AZD9750 induces the proteasome-dependent degradation of both wild-type AR and the drug-resistant mutant AR ^L702H, thereby inhibiting the AR signaling pathway. AZD9750 suppresses tumor growth in mouse prostate cancer xenograft models and has been utilized in prostate cancer research .

HY-176128

BWA-6047	PROTACs Androgen Receptor Apoptosis PARP Caspase	Cancer
BWA-6047 is an oral active PROTAC degrader targeting AR/AR-V7 and GSPT1 with DC₅₀ values of 3.7, 3.0 and 1.2 nM in 22Rv1 cells. BWA-6047 suppresses the expression of AR downstream target genes and and transcriptional activity. BWA-6047 inhibits cancer cells proliferation, causes G1 phase cell cycle arrest and induces apoptosis. BWA-6047 increases cleaved-PARP-1 and cleaved-caspase-3 levels. BWA-6047 reduces growth of LNCaP xenograft tumors in mice models without obvious toxicity. BWA-6047 can be used for the research of prostate cancer .

HY-150268

Zavabresib BET-IN-16	Epigenetic Reader Domain	Cancer
Zavabresib (BET-IN-16) (Compound I) is a BET inhibitor. BET-IN-16 shows anticancer activity. Zavabresib inhibits prostate cancer cell growth, with IC₅₀ values of 0.043 and 0.034 μM against LNCaP and 22Rv1 cells, respectively .

HY-163641

AR Degrader-1	Molecular Glues Androgen Receptor E1/E2/E3 Enzyme	Cancer
AR Degrader-1 (Compound ML 2-9) is a molecular glue androgen receptor (AR) monovalent degrader. AR Degrader-1 degrades AR through DCAF16 (E3 ligase) without obvious cytotoxicity in LNCaP prostate cancer cells .

HY-W748509

Pipernonaline	Caspase Apoptosis	Cancer
Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization .

HY-146396

Anticancer agent 51	MetAP	Cancer
Anticancer agent 51 (compound 3d) is a potent anticancer agent with an K_i of 731.62 nM. Anticancer agent 51 shows anticancer activity. Anticancer agent 51 has the potential for the research of prostate cancer .

HY-158119A

PSMA-trillium Felivotide mopaxetan	PSMA	Cancer
PSMA-trillium (Felivotide mopaxetan) is a PSMA-targeted molecule that contains a highly specific PSMA-binding motif, an albumin-binding domain optimized for tumor uptake and retention, and a Macropa chelator conjugated to the α-emitter ²²⁵Ac. PSMA-trillium binds to albumin to prolong plasma retention time and binds to PSMA via its specific motif. ²²⁵Ac-PSMA-Trillium exhibits dose-dependent inhibition of LNCaP tumor growth in mice. PSMA-trillium can be used in research related to prostate cancer and metastatic castration-resistant prostate cancer .

HY-175455

LYA914	PROTACs Androgen Receptor Akt	Cancer
LYA914 is an orally active AR/AR-V7 PROTAC degrader. LYA914 targets the proteolytic degradation of the conserved DNA binding domain (DBD) of the androgen receptor (AR). LYA914 exhibits potent antiproliferative effects in Enzalutamide (HY-70002)-insensitive/resistant cells. LYA914 inhibits tumor growth in VCaP/LNCaP tumor mouse models. LYA914 can be used to study castration-resistant prostate cancer (CRPC). (Pink: AR-DBD ligand-1: HY-175456, Blue: Thalidomide: HY-14658, Pink + Black: AR-DBD ligand-Linker Conjugate 1: HY-175457, Black: Boc-piperidine-oxopiperidin: HY-175458) .

HY-N16483

Procyanidin B2-3'-O-gallate	Apoptosis Caspase Bcl-2 Family PARP Androgen Receptor	Cancer
Procyanidin B2-3'-O-gallate is a mono-gallate ester that can be found in grape seed extract. Procyanidin B2-3'-O-gallate induces cleavage of caspase-9, caspase-3, and PARP, reduces levels of Bcl-2, Bcl-Xl, and androgen receptor and induces apoptosis. Procyanidin B2-3'-O-gallate can be used for the research of prostate cancer .

HY-Y0943

Isobutyramide	Drug Metabolite	Cancer
Aldehyde Dehydrogenase Isobutyramide is an orally active liver alcohol dehydrogenase (LADH2) inhibitor. Isobutyramide inhibits ethanol metabolism and enhances differentiation-related gene expression, inducing cell cycle arrest and significantly reducing the growth rate of prostate cancer cells (LNCaP). Isobutyramide is promising for research of advanced prostate cancer .

HY-N16066

Candidusin A CHNQD-0803	AMPK Apoptosis NF-κB TNF Receptor	Inflammation/Immunology
Candidusin A (CHNQD-0803) (Compound 4) is a AMPK activator with a K_D of 47.28 nM. Candidusin A can be isolated from marine fungus Aspergillus candidus. Candidusin A has cytotoxic activity and induces apoptosis in human prostate cancer cells (22Rv1, PC-3 and LNCaP cells). Candidusin A reduces adipogenesis genes expression and fat deposition, negatively regulates the NF-κB-TNFα inflammatory axis to suppress inflammation, and ameliorates liver injury and fibrosis. Candidusin A can be used for non-alcoholic steatohepatitis (NASH) research .

HY-175248

PSMA-DIM	PSMA	Cancer
PSMA-DIM is a dimeric PSMA ligand with a K_d of 37.09 nM for LNCaP cells. PSMA-DIM can be radiolabeled with [ ⁶⁸Ga]Ga to form [ ⁶⁸Ga]Ga-PSMA-DIM. [ ⁶⁸Ga]Ga-PSMA-DIM can effectively distinguish between cells and animal models with different expression levels of PSMA. [ ⁶⁸Ga]Ga-PSMA-DIM exhibits high LNCaP cells uptake and tumor uptake peak values. PSMA-DIM can be used for the study of prostate cancer (PCa) .

HY-120581

ML388	PGE synthase	Cancer
ML388 is a potent and selective hydroxyprostaglandin dehydrogenase (HPGD) inhibitor with an IC₅₀ of 34 nM. ML388 induces PGE2 production in A549 cells and LNCaP prostate cancer cells .

HY-118091A

Bexlosteride LY300502	5 alpha Reductase	Cancer
Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer .

HY-124585

Y08060	Epigenetic Reader Domain	Cancer
Y08060 is a selective BET inhibitor. Y08060 inhibits the viability of C4-2B and LNCaP cell lines with IC₅₀ values of 3.23 and 4.41 μM. Y08060 can suppress colony formation as well as AR expression in prostate cancer cell line. Y08060 can be studied in prostate cancer research .

HY-N15449

Vicanicin	HSP Caspase Apoptosis Reactive Oxygen Species (ROS) Bcl-2 Family	Cancer
Vicanicin is a depsidone compound found in lichens. Vicanicin inhibits the expression of Hsp70, regulates the redox-sensitive mechanisms within cells, promotes the increase of reactive oxygen species (ROS) in cancer cells, changes the Bax/Bcl-2 ratio, activates caspase-3, and triggers apoptosis. Vicanicin inhibits cell growth and induces apoptosis in androgen-sensitive (LNCaP) and androgen-insensitive (DU-145) human prostate cancer cells. Vicanicin is promising for research of prostate cancer .

HY-141830

SYY-B029-2	Histone Acetyltransferase	Cancer
SYY-B029-2 is a potent histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 1.4 nM. SYY-B029-2 cell growth of human mantle cell lymphoma (MCL) cell line MAVER-1 and human castration resistant prostate cancer cell line LNCaP clone FGC, with IC₅₀ values of 15 nM and 13 nM, respectively .

HY-149914

WCA-814	Androgen Receptor	Cancer
WCA-814 is an androgen receptor (AR) antagonist-Hsp90 inhibitor conjugate. WCA-814 induces the degradation of full-length and AR-V7. WCA-814 has cytotoxic effect in prostatic cancer cells (IC₅₀: 171.2 nM, 26.5 nM for LNCaP, 22Rv1 cell) .

HY-151533

PBRM1-BD2-IN-6	Epigenetic Reader Domain	Cancer
PBRM1-BD2-IN-6 is a potent PBRM1 bromodomain inhibitor with an IC₅₀ value of 0.22 μM. PBRM1-BD2-IN-6 shows antiproliferation activity. PBRM1-BD2-IN-6 has the potential for the research of PBRM1-dependent cancer .

HY-W437569

Melicopine	Parasite Insecticide	Infection Cancer
Melicopine is an alkaloid found in Z. simulans with antimalarial and anticancer activities. It exhibits inhibitory activity against chloroquine-sensitive 3D7 and chloroquine-resistant Dd2 strains of P. falciparum, with IC₅₀ values of 29.7 and 33.7 µg/mL, respectively. Melicopine is cytotoxic to prostate cancer cells PC-3M and LNCaP (IC₅₀ values of 47.9 and 37.8 µg/mL), but has no effect on non-cancerous HEK293 cells (IC₅₀ greater than 100 µg/mL). Melicopine holds promise for research in anticancer and anti-infection fields .

HY-163510

AR/AR-V7-IN-1	Androgen Receptor	Cancer
AR/AR-V7-IN-1 (Compound 20i) is an AR/ARV7 inhibitor (IC₅₀ = 172.85 nM). AR/AR-V7-IN-1 potently inhibits cell growth with IC₅₀ values of 4.87 and 2.07 μM in the LNCaP and 22RV1 cell lines, respectively. AR/AR-V7-IN-1 exhibits effective tumor growth inhibition in the 22RV1 xenograft study. AR/AR-V7-IN-1 can be used for the research of prostate cancer .

HY-P1793A

α-Casein (90-95) TFA	Opioid Receptor Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology Cancer
α-Casein (90-95) TFA is a partial agonist of opioid receptors and a copper ion ligand, with opioid activity. α-Casein (90-95) TFA inhibits the secretion of β-hexosaminidase by rat peritoneal mast cells (PMC) with IC₅₀= 0.1 μM. α-Casein (90-95) TFA inhibits the proliferation of prostate cancer cells LNCaP, DU145, and PC3 with IC₅₀ of 0.94 nM, 137 nM, and 6.92 nM, respectively. α-Casein (90-95) TFA activates G_i-like proteins through a membrane-assisted, receptor-independent pathway, or reversibly binds to opioid receptors, inducing intracellular calcium release and conformational changes, and exerts the activity of promoting mast cell secretion and inhibiting tumor cell proliferation. α-Casein (90-95) TFA can be used in the study of the mechanisms of allergic diseases and prostate cancer .

HY-135732

SK33	Androgen Receptor	Cancer
SK33, a trifluoromethylated enobosarm analog, is a potent, and tissue selective anti-androgen. SK33reduces androgen receptor (AR) transcriptional activity .

HY-133044

Boc-Pip-alkyne-Ph-COOH	PROTAC Linkers	Cancer
Boc-Pip-alkyne-Ph-COOH is a PROTAC linker, which refers to the alkyl/ether composition. Boc-Pip-alkyne-Ph-COOH can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020). ARD-266 effectively induces degradation of androgen receptor (AR) protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM . Boc-Pip-alkyne-Ph-COOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N10265

Stephacidin B	Endogenous Metabolite	Cancer
Stephacidin B is a fungal metabolite. Stephacidin B shows in vitro cytotoxicity against a panel of human tumor cell lines. Stephacidin B shows the strongest cytotoxicity against testosterone-dependent prostate LNCaP cancer cells .

HY-144755

MC2652	Histone Demethylase	Cancer
MC2652 (compound 1a) is a potent LSD1 inhibitor. MC2652 displays high inhibiting effects in MV4-11 and NB4 leukaemia cells. MC2652 shows antiproliferative activity against prostate cancer LNCaP cells .

HY-121619

Jacaric acid	Apoptosis	Inflammation/Immunology Cancer
Jacaric acid is a conjugated linolenic acid, which inhibits viability in cells PC-3 (IC₅₀ is 11.8 μM), LNCaP (IC₅₀ is 2.2 μM) and DLD-1, induces apoptosis and necrosis . Jacaric acid exhibits anticaner activity against prostate cancer and adenocarcinoma . Jacaric acid exhibits immunomodulating activity in murine peritoneal macrophages as an immunopotentiator . Jacaric acid is orally active.

HY-144758

LSD1-IN-17	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-17 (compound 5b) is a potent LSD1 inhibitor. LSD1-IN-17 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 17.2 μM .

Cat. No.	Product Name	Type

HY-D3353

PSMA-SulfoCy7

Fluorescent Dyes

PSMA-SulfoCy7 is a high-affinity imaging agent targeting PSMA/GCPII (with a K_i of 18.1 nM for human PSMA). PSMA-SulfoCy7 regulates PSMA-dependent NAAG hydrolysis. PSMA-SulfoCy7 exhibits excellent in vivo imaging capability, enabling clear visualization of PSMA-expressing tumors in xenograft models, with no obvious toxicity even at a dose of 87.9 mg/kg. PSMA-SulfoCy7 is widely used in prostate cancer-related studies .

HY-D3189

5GluAF-2MeTG

Fluorescent Dyes

5GluAF-2MeTG is an activatable fluorescent probe targeting the glutamate carboxypeptidase (CP) activity of PSMA (Ex/Em=490/500-600 nm). After being hydrolyzed by PSMA, 5GluAF-2MeTG releases a cell membrane-permeable fluorescent product, and achieves fluorescence activation by disrupting donor-excited photoinduced electron transfer (d-PeT). 5GluAF-2MeTG enables fluorescence imaging of live PSMA-expressing prostate cancer cells in vitro and visualizes the carboxypeptidase activity of PSMA. 5GluAF-2MeTG can be used to detect prostate cancer regions in preclinical excised tissue specimens .

HY-D3347

DUPA-FITC

Fluorescent Dyes

DUPA-FITC is a fluorescent reagent targeting PSMA, which specifically binds to prostate cancer cells expressing PSMA without non-specific binding to normal blood cells. DUPA-FITC can label PSMA-expressing prostate cancer cells in whole blood, followed by internalization and trafficking to acidic intracellular endosomes, during which the fluorescence is quenched. When combined with flow cytometry and density gradient centrifugation enrichment, DUPA-FITC enables quantitative analysis of circulating tumor cells in peripheral blood samples from prostate cancer patients .

Cat. No.	Product Name	Target	Research Area

HY-P1793

α-Casein (90-95)	Opioid Receptor Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology Cancer
α-Casein (90-95) is a partial agonist of opioid receptors and a copper ion ligand, with opioid activity. α-Casein (90-95) inhibits the secretion of β-hexosaminidase by rat peritoneal mast cells (PMC) with IC₅₀= 0.1 μM. α-Casein (90-95) inhibits the proliferation of prostate cancer cells LNCaP, DU145, and PC3 with IC₅₀ of 0.94 nM, 137 nM, and 6.92 nM, respectively. α-Casein (90-95) activates G_i-like proteins through a membrane-assisted, receptor-independent pathway, or reversibly binds to opioid receptors, inducing intracellular calcium release and conformational changes, and exerts the activity of promoting mast cell secretion and inhibiting tumor cell proliferation. α-Casein (90-95) can be used in the study of the mechanisms of allergic diseases and prostate cancer .

HY-P1793A

α-Casein (90-95) TFA	Opioid Receptor Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology Cancer
α-Casein (90-95) TFA is a partial agonist of opioid receptors and a copper ion ligand, with opioid activity. α-Casein (90-95) TFA inhibits the secretion of β-hexosaminidase by rat peritoneal mast cells (PMC) with IC₅₀= 0.1 μM. α-Casein (90-95) TFA inhibits the proliferation of prostate cancer cells LNCaP, DU145, and PC3 with IC₅₀ of 0.94 nM, 137 nM, and 6.92 nM, respectively. α-Casein (90-95) TFA activates G_i-like proteins through a membrane-assisted, receptor-independent pathway, or reversibly binds to opioid receptors, inducing intracellular calcium release and conformational changes, and exerts the activity of promoting mast cell secretion and inhibiting tumor cell proliferation. α-Casein (90-95) TFA can be used in the study of the mechanisms of allergic diseases and prostate cancer .

HY-P11591

PDI2 PSMA-DOTA-PEI2	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer .

HY-P11658

Anticancer peptoid 1 Peptoid 1	Peptides	Cancer
Anticancer peptoid 1 (Peptoid 1) is a peptoid with antitumor activity. Anticancer peptoid 1 exerts cytotoxicity primarily via plasma membrane damage. Anticancer peptoid 1 exerts cytotoxicity against a broad range of cancer cell lines, including those with multidrug resistance. Anticancer peptoid 1 inhibits tumor growth in a human breast cancer xenotransplantation mouse model without noticeable acute adverse effects. Anticancer peptoid 1 can be used for the research of cancer, such as breast cancer, and prostate cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992209

Anti-CD318/CDCP1 Antibody (25A11)	Transmembrane Glycoprotein	Cancer
Anti-CD318/CDCP1 Antibody (25A11) is an anti-CDCP1 antibody. Anti-CD318/CDCP1 Antibody (25A11) drives the internalization of antibody-CDCP1 complexes, inhibits cancer cell migration and invasion, and blocks downstream migration/invasion signaling pathways. When conjugated with saponin, Anti-CD318/CDCP1 Antibody (25A11) mediates the killing of prostate cancer cells. When conjugated with saponin, this antibody acts as an immunotoxin to inhibit the growth and metastasis of primary prostate tumors in mouse xenograft models. Anti-CD318/CDCP1 Antibody (25A11) is applicable to prostate cancer-related research .

HY-P992094

Capromab	PSMA	Cancer
Capromab is an anti-human PSMA-targeting monoclonal antibody. Capromab binds specifically to the intracellular domain of PSMA, does not undergo internalization after binding, and targets necrotic cells with disrupted membranes. Capromab can be used for the research of prostate cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N11908

α-Santalol cis-α-Santalol	Structural Classification Santalum album Linn. Terpenoids Sesquiterpenes Plants Source Classification Santalaceae	Akt Survivin Apoptosis Caspase PARP
α-Santalol (cis-α-Santalol), a naturally occurring sesquiterpene, is an orally active anticancer agent and apoptosis inducer. α-Santalol activates caspase-3 to drive apoptotic processes. >α-Santalol induces apoptosis, decreases cell viability, and causes PARP cleavage in human prostate cancer cells. α-santalol inhibits Akt/Survivin pathway to induce cell death. α-Santalol can be used for the research of prostate cancer and diabetes mellitus .

HY-N0475

Triptophenolide Hypolide; (+)-Triptophenolide	Structural Classification Monophenols Classification of Application Fields Terpenoids Celastraceae Other Diseases Phenols Diterpenoids Tripterygium wilfordii Hook. f. Plants Disease Research Fields Source Classification	Androgen Receptor Pyroptosis Caspase Bcl-2 Family Apoptosis
Triptophenolide (Hypolide) is a colorless crystal isolated from the ethyl acetate extract of Tripterygium wilfordii. Triptophenolide is an orally active pan‑antagonist of the androgen receptor (AR) with an IC₅₀ of 467 nM against human wild‑type AR. Triptophenolide reduces AR expression, inhibits AR nuclear translocation, downregulates prostate‑specific antigen mRNA levels, and suppresses the growth of AR‑positive prostate cancer cells. Triptophenolide shows anti-tumor effects against breast cancer by inhibiting cell proliferation and migration, inducing G1-phase arrest and apoptosis, repressing xenograft tumor growth. Triptophenolide inhibits pyroptosis, alleviates tissue inflammation, and ameliorates synovial injury. Triptophenolide can be used for the study of prostate cancer, rheumatoid arthritis and breast cancer .

HY-N7510

12-O-Methylcarnosic acid 12-Methoxycarnosic acid	Classification of Application Fields Paramacrolobium coeruleum (Taub.) J.Léonard Cylicodiscus gabunensis Harms Plants Infection Monophenols Terpenoids Labiatae Phenols Diterpenoids Disease Research Fields Source Classification Cancer	5 alpha Reductase
12-O-Methylcarnosic acid (12-Methoxycarnosic acid), a diterpene carnosic acid isolated from the acetone extract of Salvia microphylla, is an active constituent of 5α-reductase inhibition with an IC₅₀ value of 61.7 μM. 12-O-Methylcarnosic acid inhibits proliferation in LNCaP cells. 12-O-Methylcarnosic acid has antioxidant, anti-cancer and antimicrobial activity .

HY-N3999

Venuloside A ESK246	Other Monoterpenes Terpenoids Pittosporaceae Plants Pittosporum venulosum F.Muell. Source Classification	Others
Venuloside A is a potent inhibitor of LAT3. Venuloside A inhibits the leucine uptake in LNCaP prostate cancer cells with an IC₅₀ of 8.12 μM .

HY-W748509

Pipernonaline	Piper longum Linn. Alkaloids Piperidine Alkaloids Piperaceae Plants Source Classification	Caspase Apoptosis
Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization .

HY-N16483

Procyanidin B2-3'-O-gallate	Structural Classification Vitis vinifera cv. Zalema Phenols Polyphenols Plants Vitaceae Source Classification	Apoptosis Caspase Bcl-2 Family PARP Androgen Receptor
Procyanidin B2-3'-O-gallate is a mono-gallate ester that can be found in grape seed extract. Procyanidin B2-3'-O-gallate induces cleavage of caspase-9, caspase-3, and PARP, reduces levels of Bcl-2, Bcl-Xl, and androgen receptor and induces apoptosis. Procyanidin B2-3'-O-gallate can be used for the research of prostate cancer .

HY-N16066

Candidusin A CHNQD-0803	Monophenols Microorganisms Phenols Source Classification	AMPK Apoptosis NF-κB TNF Receptor
Candidusin A (CHNQD-0803) (Compound 4) is a AMPK activator with a K_D of 47.28 nM. Candidusin A can be isolated from marine fungus Aspergillus candidus. Candidusin A has cytotoxic activity and induces apoptosis in human prostate cancer cells (22Rv1, PC-3 and LNCaP cells). Candidusin A reduces adipogenesis genes expression and fat deposition, negatively regulates the NF-κB-TNFα inflammatory axis to suppress inflammation, and ameliorates liver injury and fibrosis. Candidusin A can be used for non-alcoholic steatohepatitis (NASH) research .

HY-N15449

Vicanicin	Natural Products Microorganisms Source Classification	HSP Caspase Apoptosis Reactive Oxygen Species (ROS) Bcl-2 Family
Vicanicin is a depsidone compound found in lichens. Vicanicin inhibits the expression of Hsp70, regulates the redox-sensitive mechanisms within cells, promotes the increase of reactive oxygen species (ROS) in cancer cells, changes the Bax/Bcl-2 ratio, activates caspase-3, and triggers apoptosis. Vicanicin inhibits cell growth and induces apoptosis in androgen-sensitive (LNCaP) and androgen-insensitive (DU-145) human prostate cancer cells. Vicanicin is promising for research of prostate cancer .

HY-W437569

Melicopine	Alkaloids Cornaceae Cornus officinalis Sieb. et Zucc. Acridone Alkaloids Plants Source Classification	Parasite Insecticide
Melicopine is an alkaloid found in Z. simulans with antimalarial and anticancer activities. It exhibits inhibitory activity against chloroquine-sensitive 3D7 and chloroquine-resistant Dd2 strains of P. falciparum, with IC₅₀ values of 29.7 and 33.7 µg/mL, respectively. Melicopine is cytotoxic to prostate cancer cells PC-3M and LNCaP (IC₅₀ values of 47.9 and 37.8 µg/mL), but has no effect on non-cancerous HEK293 cells (IC₅₀ greater than 100 µg/mL). Melicopine holds promise for research in anticancer and anti-infection fields .

HY-N10265

Stephacidin B	Alkaloids Microorganisms Classification of Application Fields Disease Research Fields Alkaloid Dimers Cancer Source Classification	Endogenous Metabolite
Stephacidin B is a fungal metabolite. Stephacidin B shows in vitro cytotoxicity against a panel of human tumor cell lines. Stephacidin B shows the strongest cytotoxicity against testosterone-dependent prostate LNCaP cancer cells .

HY-121619

Jacaric acid	Caprifoliaceae Ketones, Aldehydes, Acids Plants Centranthus ruber (L.) DC Source Classification	Apoptosis
Jacaric acid is a conjugated linolenic acid, which inhibits viability in cells PC-3 (IC₅₀ is 11.8 μM), LNCaP (IC₅₀ is 2.2 μM) and DLD-1, induces apoptosis and necrosis . Jacaric acid exhibits anticaner activity against prostate cancer and adenocarcinoma . Jacaric acid exhibits immunomodulating activity in murine peritoneal macrophages as an immunopotentiator . Jacaric acid is orally active.

HY-N1338

Royleanone NSC 122417	Quinones Anthraquinones Labiatae Plants Source Classification Vachellia nilotica (L.) P. J. H. Hurter & Mabb.	mTOR Akt
Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis, also inhibits cell migration potential, inhibits mTOR/PI3/AKT signaling pathway in LNCaP prostate cancer cells .

HY-N8856

Angelol M	Leguminosae Campylotropis hirtella (Franch.) Schindl. Coumarins Phenylpropanoids Plants Source Classification	Others
Angelol M,isolated from the roots of Angelica gigas Nakai, shows activity in inhibiting prostate specific antigen (PSA) secreted from androgen dependent prostate cancer cell line, LNCaP cells .

HY-129672

Thelenotoside B 25-Dihydrostichorrenoside E	Other Terpenoids Animals Terpenoids Source Classification	Drug Derivative
Thelenotoside B (25-Dihydrostichorrenoside E) shows strong cytotoxicities against five cancer cell lines as HepG2, KB, LNCaP, MCF7 and SK-Mel2 with the IC₅₀ values from 0.95 ± 0.08 to 1.90 ± 0.13 μM. Thelenotoside B is a triterpene tetraglycoside .

HY-N7510R

12-O-Methylcarnosic acid (Standard) 12-Methoxycarnosic acid (Standard)	Structural Classification Monophenols Paramacrolobium coeruleum (Taub.) J.Léonard Terpenoids Labiatae Phenols Diterpenoids Cylicodiscus gabunensis Harms Plants Source Classification	Reference Standards 5 alpha Reductase
12-O-Methylcarnosic acid (Standard) is the analytical standard of 12-O-Methylcarnosic acid. This product is intended for research and analytical applications. 12-O-Methylcarnosic acid (12-Methoxycarnosic acid), a diterpene carnosic acid isolated from the acetone extract of Salvia microphylla, is an active constituent of 5α-reductase inhibition with an IC₅₀ value of 61.7 μM. 12-O-Methylcarnosic acid inhibits proliferation in LNCaP cells. 12-O-Methylcarnosic acid has antioxidant, anti-cancer and antimicrobial activity .

HY-N16404

Asperindole A	Structural Classification Alkaloids Microorganisms Terpenoids Diterpenoids Indole Alkaloids Source Classification	Apoptosis Endogenous Metabolite
Asperindole A is an indole-diterpene alkaloid. Asperindole A can be isolated from fungus Aspergillus sp. KMM 4676. Asperindole A induces Apoptosis. Asperindole A exerts cytotoxic activity against hormone-resistant and hormone-sensitive prostate cancer cells .

HY-N17444

3β-Hydroxy-24-methylenecholest-5-en-7-one	Triterpenes Structural Classification Animals Terpenoids Source Classification	Others
3β-Hydroxy-24-methylenecholest-5-en-7-one (Compound 4) is a steroid found in the soft coral Sinularia nanolobata. 3β-Hydroxy-24-methylenecholest-5-en-7-one does not exhibit cytotoxic activity against human cancer cells .

Cat. No.	Product Name	Chemical Structure

HY-70002S1

Enzalutamide-d6
Enzalutamide-d₆ (MDV3100-d₆) is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC₅₀ of 36 nM in LNCaP prostate cells .

HY-70002S

Deutenzalutamide
Deutenzalutamide (Enzalutamide-d₃) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells .

HY-16985S

Darolutamide-d4

Darolutamide-d₄ (ODM-201-d₄) is deuterium labeled Darolutamide (HY-16985). Darolutamide (ODM-201) is an orally active competitive androgen receptor (AR) antagonist, with a K_i of 11 nM for rat wild-type AR (wtAR) and an IC₅₀ of 26 nM for human wild-type AR (hAR)-mediated transcriptional activation . Darolutamide inhibits testosterone-induced AR nuclear translocation and transcriptional activation . Darolutamide exerts selective effects on AR-positive cells by inhibiting AR-dependent signaling pathways, and its active metabolite retains full antagonistic activity against AR mutants . Darolutamide can be used for the research of prostate cancer, including androgen receptor-dependent prostate cancer .

HY-19337S1

Ketodarolutamide-d6

Ketodarolutamide-d₆ (BAY 1896953-d₆) is the deuterium labeled Ketodarolutamide (HY-19337). Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a K_i value of 8 nM for rat wild-type AR and an IC₅₀ value of 38 nM in AR-HEK293 cells . Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs . Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer .

HY-19337S

Ketodarolutamide-d3

Ketodarolutamide-d₃ (BAY 1896953-d₃) is the deuterium labeled Ketodarolutamide (HY-19337). Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a K_i value of 8 nM for rat wild-type AR and an IC₅₀ value of 38 nM in AR-HEK293 cells . Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs . Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer .

Cat. No.	Product Name		Classification

HY-133020

ARD-266		PROTAC Synthesis
ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM . ARD-266 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-16247

Apoptone HE3235		Alkynes
Apoptone (HE3235) is an orally active 3β-androstanediol analog. Apoptone reduces the expression of androgen receptor (Androgen receptor) and decreases intratumoral androgen levels. Apoptone exhibits anticancer activity against castration-resistant prostate cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

LNCaP cancer cells

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products